Background on Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder predominantly affecting boys, characterized by progressive muscle wasting that often results in wheelchair confinement during childhood and significantly reduces life expectancy to the 20s or 30s. Currently, no definitive cure exists; however, Givinostat, also known as Duvyzat, has shown promise as the first treatment capable of slowing the disease’s progression. This medication aids in reducing inflammation and promoting muscle regeneration.

Advocacy for Givinostat Treatment

In late 2024, Givinostat received approval from UK regulators for patients aged six and over, yet many families found the treatment largely inaccessible. By April 2025, reports indicated minimal availability, with only a small number of children in England and Wales starting treatment, and no access in Scotland or Northern Ireland.

Mothers like Nicola Rankin, whose 12-year-old son Michael suffers from DMD, expressed their despair: “It is heartbreaking to know there is a drug out there that could slow [their child’s] condition but [they] can’t access it.”

Unified Efforts for Change

In early 2025, families impacted by DMD, under the guidance of human rights lawyer Aamer Anwar, banded together to urge action from the Scottish Government. They met with Health Secretary Neil Gray, who committed to advocating for the expedited rollout of Givinostat through NHS channels. Despite initial logistical challenges cited by health boards, there was a commitment to establish early access programs, prompting outreach to affected families.

Broader Impact and Future Goals

This grassroots initiative seeks not only to address immediate medical needs but also to inspire systemic reform regarding the adoption of rare-disease treatments within the NHS. The ultimate goal is to advocate for equitable, faster access to necessary medications, reducing geographical disparities that currently hinder treatment availability. What began as a single family’s plea has transformed into a widespread movement, offering hope for many Scottish families facing DMD.

Also Noteworthy: Landmark Legal Developments in Scotland

In addition to healthcare advocacy, significant strides have been made in legal circles regarding the definition of “woman” in the Equality Act 2010. For Women Scotland, a women’s rights group founded in 2018, successfully fought for a clarification that biological sex at birth should be the defining factor. This pivotal ruling from the Supreme Court in April 2025 has sparked ongoing discussions regarding equality and rights in Scottish law.

Criminal Justice Reform Efforts

Another impactful campaign led by Miss M, a survivor of sexual violence, in collaboration with Rape Crisis Scotland, sought the abolition of the “Not Proven” verdict, a legal option in Scottish courts criticized for contributing confusion and stigma, particularly in sexual offence cases. The campaign culminated in the passing of the Victims, Witnesses and Justice Reform (Scotland) Bill in 2023, leading to the removal of the controversial verdict. This reform reflects a significant change in the justice system aimed at better supporting survivors.